Neogenomics Inc (NASDAQ:NEO) price on current trading day, rose 3.54% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $9.95.
A look at the stock’s price movement, the close in the last trading session was $9.61, moving within a range at $9.38 and $10.175. The beta value (5-Year monthly) was 1.276. Turning to its 52-week performance, $19.11 and $8.98 were the 52-week high and 52-week low respectively. Overall, NEO moved -19.79% over the past month.
Neogenomics Inc’s market cap currently stands at around $1.28 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-17.
Analysts have a consensus estimate of 171.68M for the company’s revenue for the quarter, with a low and high estimate of 169.22M and 174.7M respectively. The average forecast suggests up to a 9.88% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 738.02M, representing a 11.72% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NEO is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 7 recommend NEO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NEO’s current price about -2.39% and -22.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.98, while 7-day volatility ratio is 6.28% and 8.18% in the 30-day chart. Further, Neogenomics Inc (NEO) has a beta value of 1.40, and an average true range (ATR) of 0.83. Analysts have given the company’s stock an average 52-week price target of $18, forecast between a low of $18 and high of $18. Looking at the price targets, the low is -80.9% off current price level while to achieve the yearly target high, price needs to move -80.9%. Nonetheless, investors will most likely welcome a -80.9% jump to $18 which is the analysts’ median price.
If we refocus on Neogenomics Inc (NASDAQ:NEO), historical trading data shows that trading volumes averaged 1.49 over the past 10 days and 1.21 million over the past 3 months. The company’s latest data on shares outstanding shows there are 128.15 million shares.
The 1.20% of Neogenomics Inc’s shares are in the hands of company insiders while institutional holders own 97.19% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.49 million on 2025-02-28, giving us a short ratio of 3.09. The data shows that as of 2025-02-28 short interest in Neogenomics Inc (NEO) stood at 376.99999999999994 of shares outstanding, with shares short falling to 3.77 million registered in 2025-01-31. Current price change has pushed the stock -39.62% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NEO stock continues to rise going into the next quarter.
